Schmidt et al. reported that high MALAT1 expression correlated with poor prognosis in NSCLC, and when combined with thymosin β4, it served as an independent prognostic indicator for early-stage disease (Schmidt et al., 2011). This evidence concerns the gene MALAT1 and non-small cell lung carcinoma.